Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 20;77(6):910–916. doi: 10.1093/cid/ciad304

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 4. — Development of rabies virus (RABV)-specific CD4⁺ and CD8⁺ T cells 28 days after rabies vaccine: Frequency of antigen-specific CD4⁺ and CD8⁺ T cells, at baseline (D0) and 28 d after initial vaccination (D28) via intradermal (ID) scheme (green, A and C) or intramuscular (IM) scheme (blue, B and D) measured after 24 h stimulation with GlyRab peptide pool. Induced expression of CD25 and OX40 was used to identify RABV-specific CD4⁺ T cells; and CD137 and CD69 to identify RABV-specific CD8⁺ T cells. RABV-specific T cells were assessed for 17 ID-vaccinated individuals at D0 and D28, respectively, and for 12 IM-vaccinated study participants at D0 and D28, respectively. Each dot represents a single individual. Statistics: Wilcoxon matched-pairs signed rank test. *P < .05.